phrykt

Humacyte, Inc. (HUMA): who owns it and who trades it

As of Nov 16, 2026, HUMA insiders reported 1 open-market sale worth $41.3K and 5 purchases worth $90K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Dale A. Sander (CFO), with $41.3K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Humacyte

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns HUMA

163 funds and institutions reported HUMA shares worth $58.2M at the end of Q2 2026, about 34% of the company. The largest holder is Vanguard Capital Management LLC with 4.6%.

Funds and institutions (13F) 34%Everyone else 66%

10 largest owners, by share of the company

Vanguard Capital Management LLC4.6%
ANTIPODES PARTNERS Ltd4.6%
Alyeska Investment Group, L.P.2.7%
Davidson Kempner Capital Management LP2.3%
BlackRock, Inc.2.2%
Great Point Partners LLC1.7%
UBS Group AG1.3%
AQR Capital Management LLC1.2%
Geode Capital Management, LLC1.0%
Millennium Management LLC0.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Vanguard Capital Management LLC10.11M4.55%$7.9M+41%
ANTIPODES PARTNERS Ltd10.10M4.55%$7.9M+77%
Alyeska Investment Group, L.P.6.02M2.71%$4.7M–
Davidson Kempner Capital Management LP5.00M2.25%$3.9M–
BlackRock, Inc.4.84M2.18%$3.8M-61%
Great Point Partners LLC3.75M1.69%$2.9MNo change
UBS Group AG2.84M1.28%$2.2M+2%
AQR Capital Management LLC2.60M1.17%$2M+35%
Geode Capital Management, LLC2.19M0.98%$1.7M-40%
Millennium Management LLC1.91M0.86%$1.5M+1665%
Susquehanna International Group, LLP1.70M0.77%$1.3M+61%
Citadel Advisors LLC1.44M0.65%$1.1M–
Charles Schwab Investment Management Inc1.35M0.61%$1.1M+5%
Sixth Street Partners Management Company, L.P.1.35M0.61%$1.1M–
Vanguard Fiduciary Trust Co1.18M0.53%$921K+17%
Hrt Financial LP1.09M0.49%$850K–
LPL Financial LLC1.03M0.46%$800K+19%
Gsa Capital Partners LLP1.01M0.45%$785K+303%
Private Advisor Group, LLC965,0910.43%$753K+16%
State Street Corp842,5370.38%$658K-72%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, HUMA insiders reported $90K of open-market purchases and $41.3K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$90K
5 trades, 3 people
Sales, 12 months
$41.3K
1 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Sep 14, 2026
Filed Sep 15, 2026

Purchases and sales by month

$59.8K$59.8KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 14, 2026Keith Anthony JonesDirectorPurchase10,000$0.56$5.6KForm 4
Aug 20, 2026Keith Anthony JonesDirectorPurchase10,000$0.69$6.9KForm 4
Aug 17, 2026Keith Anthony JonesDirectorPurchase30,000$0.59$17.7KForm 4
May 19, 2026Kathleen SebeliusDirectorPurchase56,818$0.88$50KForm 4
May 18, 2026Michael T. ConstantinoDirectorPurchase11,000$0.89$9.8KForm 4
May 18, 2026Dale A. SanderCFOSale45,887$0.90$41.3KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Kathleen SebeliusDirector$50K–May 19, 2026
Dale A. SanderCFO and Chief Corp. Dev. Off–$41.3KMay 18, 2026
Keith Anthony JonesDirector$30.2K–Sep 14, 2026
Michael T. ConstantinoDirector$9.8K–May 18, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

HUMA short interest

High short interest. 10.1% of HUMA shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went down 32%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 28.07M HUMA shares were sold short, 10.1% of the shares outstanding, down 7.2% from the report before. At the average daily volume of 3.91M shares, buying them all back would take about 7.2 trading days (days to cover).

Shares short, % of all shares

10.1%May 15Oct 3019.8%

Days to cover

7.2May 15Oct 308.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202628.07M10.11%-7%3.91M7.2
Oct 15, 202630.25M10.89%+3%8.27M3.7
Sep 30, 202629.40M10.58%-8%4.02M7.3
Sep 15, 202631.81M11.45%+7%4.39M7.2
Aug 31, 202629.81M10.73%-7%8.76M3.4
Aug 14, 202631.94M11.50%+1%9.50M3.4
Jul 31, 202631.49M14.18%-2%4.55M6.9
Jul 15, 202632.28M14.54%+2%9.66M3.3
Jun 30, 202631.60M14.23%-14%25.18M1.2
Jun 15, 202636.71M16.53%-9%8.95M4.1
May 29, 202640.14M18.08%-2%6.54M6.1
May 15, 202641.16M18.54%-8%7.93M5.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Humacyte company events

Humacyte filed 16 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, listing). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Sep 28, 2026LeadershipThe Board of Directors of Humacyte, Inc., appointed Scott Coward and Paul Kuznik to the Board. Filing
  3. Aug 12, 2026ResultsReleased financial results. Filing
  4. Jul 31, 2026ListingHumacyte, Inc. received a letter from the staff of The Nasdaq Stock Market LLC providing notification that, for the 30 consecutive business days ended July 30, 2026, the bid price for the Company’s common stock, par value $0.0001 per share, had closed below the minimum $1.00 per share requirement… Filing
  5. Jun 11, 2026AgreementOn June 10, 2026, Humacyte, Inc. entered into an underwriting agreement with Barclays Capital Inc., BTIG, LLC and Titan Partners Group LLC, a division of American Capital Partners, LLC, as representatives of the several underwriters named therein, relating to the issuance and sale in an… Filing
  6. Jun 10, 2026AnnouncementHumacyte, Inc. issued a press release announcing the presentation of results from its Phase 3 clinical trial (V012) of the acellular tissue engineered vessel (ATEV) in arteriovenous access for female patients with end-stage renal disease requiring hemodialysis. Filing
  7. Jun 9, 2026VoteReported shareholder vote results. Filing
  8. Jun 5, 2026AnnouncementAs previously disclosed, on May 4, 2026, Humacyte, Inc. received a letter from the staff of The Nasdaq Stock Market LLC providing notification that, for the 30 consecutive business days ended May 1, 2026, the bid price for the Company’s common stock had closed below the minimum $1.00 per share… Filing
  9. May 8, 2026ListingHumacyte, Inc. received a letter from the staff of The Nasdaq Stock Market LLC providing notification that, for the 30 consecutive business days ended May 1, 2026, the bid price for the Company’s common stock, par value $0.0001 per share, had closed below the minimum $1.00 per share requirement for… Filing
  10. Apr 24, 2026AgreementHumacyte, Inc. entered into the Third Amendment to Distribution Agreement with Fresenius Medical Care Holdings, Inc., to amend the Distribution Agreement, dated as of June 25, 2018, as amended, between the Company and Fresenius. Filing
  11. Mar 19, 2026AgreementHumacyte, Inc. entered into certain securities purchase agreements pursuant to which the Company agreed to issue and sell to certain investors in a registered direct offering 25,000,000 shares of the Company’s common stock, $0.0001 par value per share, at a price of $0.80 per share. Filing
  12. Mar 19, 2026AnnouncementBelow, is incorporated herein by reference. Filing
  13. Dec 16, 2025AgreementHumacyte, Inc. entered into a Sales Agreement with TD Securities (USA) LLC, as agent, under which the Company may offer and sell its common stock, par value $0.0001 per share, from time to time having an aggregate offering price of up to $60,000,000 during the term of the Agreement through TD… Filing
  14. Dec 15, 2025AgreementHumacyte, Inc. and Humacyte Global, Inc., a wholly-owned subsidiary of the Company, entered into a loan and security agreement with Avenue Venture Opportunities Fund II, L.P., as administrative agent and collateral agent for the lenders and as lender, which provides for a senior secured term loan… Filing
  15. Dec 15, 2025AgreementEnded an important agreement. Filing
  16. Nov 26, 2025AgreementEnded an important agreement. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Humacyte financials

Famous investors that hold HUMA

3 of the 50 well-known investors we track reported holding HUMA in their latest 13F filing. The largest position is Ken Griffin's, worth $897K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20261.73M$897K0.0%+20%
Jim Simons · Renaissance TechnologiesQ3 2026110,271$57.1K0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202612,300$6.4K0.0%No change

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Humacyte, Inc. (HUMA) stock

Who owns the most HUMA stock?

The largest reported owner of Humacyte, Inc. (HUMA) is Vanguard Capital Management LLC, with 4.6% of the company. In total, 163 funds and institutions reported holding HUMA at the end of Q2 2026, together about 34% of the shares. See the largest owners.

Are HUMA insiders buying or selling?

In the last 12 months, HUMA insiders reported 5 open-market purchases worth $90K and 1 sale worth $41.3K. The latest trade was on Sep 14, 2026. See every trade.

What is the short interest in HUMA?

As of Oct 30, 2026, 28.07M HUMA shares were sold short, 10.1% of the shares outstanding, down 7.2% from the report before. At the average daily volume of 3.91M shares, buying them all back would take about 7.2 trading days (days to cover). See the history.

Which famous investors hold HUMA?

3 of the 50 well-known investors we track reported HUMA in their latest 13F filing, including Ken Griffin, Jim Simons, Paul Tudor Jones. The largest position is worth $897K. See all holders.

Executive pay

Humacyte's chief executive was paid a total of $5.2M for the year ended Dec 31, 2025, up 478% from $905K the year before. In the last 12 months, Humacyte's executives and directors bought $90K of stock on the open market and sold $41.3K.

Chief executive, total pay$5.2MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Other top executives, average$2.1MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.